FDA Clearance Tracker · P230017-S001
PulseSelect Pulsed Field Ablation (PFA) system
Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jun 18, 2024
Approved
Time to decision
159 days
Received Jan 11, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230017-S001
- Device name
- PulseSelect Pulsed Field Ablation (PFA) system
- Applicant
- Medtronic, Inc.
- Applicant location
- Mounds View, MN
- Received
- Jan 11, 2024
- Decided
- Jun 18, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P230017
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
approval of the for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230017
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.